Active Ingredient: Azithromycin
The 28-day cure rates were similarly high in the artesunate and the standard-dose quinine cohorts: 92. Late R 1 treatment failures were seen in each of the artesunate and the standard-dose quinine cohorts.
The cure rate for cohort 3 was 73. In this cohort, 3 early treatment failures led to the termination of enrollment after 16 subjects had been enrolled.
Appropriate antibacterial therapy and follow-up tests for these diseases should be initiated if infection is confirmed. Development of Drug-Resistant Bacteria Prescribing Zithromax in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.
In clinical trials, most of the reported adverse reactions were mild to moderate in severity and were reversible upon discontinuation of the drug. Approximately 0.
Serious adverse reactions included angioedema and cholestatic jaundice. Most of the adverse reactions leading to discontinuation were related to the gastrointestinal tract.
Gastrointestinal: Dyspepsia, flatulence, vomiting, melena, and cholestatic jaundice. Genitourinary: Monilia, vaginitis, and nephritis.
Nervous System: Dizziness, headache, vertigo, and somnolence. General: Fatigue.
Allergic: Rash, photosensitivity, and angioedema. Chronic therapy with 1200 mg weekly regimen The nature of adverse reactions seen with the 1200 mg weekly dosing regimen for the prevention of Mycobacterium avium infection in severely immunocompromised HIV-infected patients were similar to those seen with short-term dosing regimens.Please enter your email address so Email Address Please enter your official email address Continue We notice that verify that you have already completed.